(Q37707387)

22 August 2017

1 reference

title

p53 family: Therapeutic targets in neuroblastoma (English)

1 reference

22 August 2017

Jennifer Wolter

1

1 reference

22 August 2017

Paola Angelini

series ordinal

2

1 reference

22 August 2017

Meredith Irwin

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

429-444

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

22 August 2017

1 reference

Familial neuroblastoma: a complex heritable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Oncogenic mutations of ALK kinase in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Activating mutations in ALK provide a therapeutic target in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Copy number variation at 1q21.1 associated with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Relative frequency and morphology of cancers in carriers of germline TP53 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Special pattern of widespread neuroblastoma with a favourable prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Chromosome 1p and 11q deletions and outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Trk receptor expression and inhibition in neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Potentiation of neuroblastoma metastasis by loss of caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Overall genomic pattern is a predictor of outcome in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p53 isoforms can regulate p53 transcriptional activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The p53 pathway: positive and negative feedback loops

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The genetics of the p53 pathway, apoptosis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p63 and p73 in human cancer: defining the network

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

An anti-apoptotic role for the p53 family member, p73, during developmental neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p73: Friend or foe in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Chemotherapy induces NEDP1-mediated destabilization of MDM2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Ubiquitin and ubiquitin-like modifications of the p53 family

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The E3 ubiquitin ligase Itch controls the protein stability of p63

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The ubiquitin-protein ligase Itch regulates p73 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Role for the p53 homologue p73 in E2F-1-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

RETRACTED: p73alpha regulation by Chk1 in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Stxbp4 regulates DeltaNp63 stability by suppression of RACK1-dependent degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Tumor spectrum analysis in p53-mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Physical interaction with human tumor-derived p53 mutants inhibits p63 activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

TAp73 knockout shows genomic instability with infertility and tumor suppressor functions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p63 protects the female germ line during meiotic arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Parc: a cytoplasmic anchor for p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p53 determines multidrug sensitivity of childhood neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

DeltaN-p73alpha accumulates in human neuroblastic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Negative autoregulation of p73 and p53 by DeltaNp73 in regulating differentiation and survival of human neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Biological and clinical role of p73 in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Role of the p53-homologue p73 in E2F1-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

N-myc modulates expression of p73 in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

DNA damage induces the rapid and selective degradation of the DeltaNp73 isoform, allowing apoptosis to occur

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Evidence that DeltaNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Induction of neuronal differentiation by p73 in a neuroblastoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

DeltaNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

MDM2 inhibitors for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Inactivation of the p53 pathway in retinoblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cyclooxygenase-2: a novel target for cancer chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

A gene signature-based approach identifies mTOR as a regulator of p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

The Connectivity Map: a new tool for biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

mTOR regulates autophagy-associated genes downstream of p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, Concanavalin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

New therapeutic targets for the treatment of high-risk neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Metformin in breast cancer: time for action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

5 '-Amino-4-imidazolecarboxamide riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

iASPP inhibition: increased options in targeting the p53 family for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p73β-Mediated Apoptosis Requires p57kip2Induction and IEX-1 Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

p63 and p73 are required for p53-dependent apoptosis in response to DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.09.176

21 January 2018

Identifiers

DOI

10.2217/FON.09.176

1 reference

22 August 2017

1 reference